Antisense-Mediated Inhibition of Human Immunodeficiency Virus (HIV) Replication by Use of an HIV Type 1-Based Vector Results in Severely Attenuated Mutants Incapable of Developing Resistance
Open Access
- 1 July 2004
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 78 (13), 7079-7088
- https://doi.org/10.1128/jvi.78.13.7079-7088.2004
Abstract
We have constructed a human immunodeficiency virus type 1 (HIV-1)-based lentiviral vector expressing a 937-base antisense sequence against the HIV-1 envelope gene. Transduction of CD4+ T lymphocytes with this vector results in expression of the therapeutic antisense sequence and subsequent inhibition of productive HIV-1 replication. In this report, we examined the effect of antisense-mediated suppression on the potential development of virus escape mutants using a permissive T-cell line cultured under conditions that over serial passages specifically allowed for generation and amplification of mutants selected for by antisense pressure. In the resulting virus clones, we found a significant increase in the number of deletions at the envelope target region (91% compared to 27.5% in wild-type HIV). Deletions were most often greater than 1 kb in length. These data demonstrate for the first time that during antisense-mediated suppression of HIV, mutants develop as a direct result of selective pressure on the HIV genomic RNA. Interestingly, in clones where deletions were not observed, there was a high rate of A-G transitions in mutants at the antisense target region but not outside this region, which is consistent with those mutations that are predicted as a result of antisense-mediated modification of double-stranded RNA by the enzyme double-stranded RNA-specific adenosine deaminase. These clones were not found to be escape mutants, as their replicative ability was severely attenuated, and they did not replicate in the presence of vector.Keywords
This publication has 58 references indexed in Scilit:
- Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral loadMolecular Therapy, 2004
- In Vivo Selection for Human and Murine Hematopoietic Cells Transduced with a Therapeutic MGMT Lentiviral Vector that Inhibits HIV ReplicationMolecular Therapy, 2004
- LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1Science, 2003
- A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined ImmunodeficiencyNew England Journal of Medicine, 2003
- Erratum: Biochemical networking contributes more to genetic buffering in human and mouse metabolic pathways than does gene duplicationNature Genetics, 2002
- Adherence to Antiretroviral Therapy by Human Immunodeficiency Virus–Infected PatientsThe Journal of Infectious Diseases, 2002
- Effective expression of small interfering RNA in human cellsNature Biotechnology, 2002
- Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisenseGene Therapy, 2002
- Inhibition of Human Immunodeficiency Virus Type 1 by Packageable, Multigenic Antisense RNAAntisense and Nucleic Acid Drug Development, 2000
- Hematologic Recovery in Mice Transplanted with Bone Marrow Stem Cells Expressing Anti-Human Immunodeficiency Virus GenesHuman Gene Therapy, 1999